Company intelligence / Profile preview

Neurovation

New York City, New York, United Statesneurovationlabs.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Currently developing a PTSD diagnostic and companion treatment based on the discovery that PTSD may be manifested through enduring increases in glutamate receptor subunit GluA1 in the basolateral amygdala. Lead asset is a small molecule Negative Allosteric Modulator of amygdala-specific AMPA receptors.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (Negative Allosteric Modulator)
Industry: Biotech

Drug pipeline

1 asset

GluA1 NAM

Pre-clinical

Indications: Post-traumatic stress disorder

Partnerships

U.S. Air Force's AFWERX ProgramAir Force Special Operations Command (AFSOC) 24th Special Operations WingU.S. Army xTech program

Beyond the preview

Go deeper on Neurovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurovation.

Explore the full profile